TY - JOUR
T1 - The expression of insulin-like growth factor 2 messenger rna-binding protein 3 in langerhans cell histiocytosis and langerhans cell sarcoma
AU - Yashige, Konomi
AU - Kataoka, Tatsuki R.
AU - Yamada, Yosuke
AU - Maeda, Hirona
AU - Oji-Tsujimura, Marina
AU - Yamamoto, Tetsurou
AU - Takei, Yusuke
AU - Moriyoshi, Koki
AU - Ono, Kazuo
AU - Kaku, Yo
AU - Tabata, Tetsuya
AU - Murakami, Ichiro
AU - Nakamine, Hirokazu
AU - Haga, Hironori
N1 - Publisher Copyright:
©2021 Tohoku University Medical Press.
PY - 2021/9
Y1 - 2021/9
N2 - Langerhans cell neoplasms, which include Langerhans cell histiocytosis and Langerhans cell sarcoma, are tumors that originate from dendritic cells. Langerhans cell sarcoma is defined as a high-grade neoplasm with overtly malignant cytological features and the Langerhans cell-like phenotype, and generally has a poorer prognosis and more aggressive phenotype than Langerhans cell histiocytosis. Insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types; its expression is often associated with a poor prognosis and aggressive phenotype. Here, we used immunohistochemistry to evaluate IGF2BP3 expression in Langerhans cell neoplasms. IGF2BP3 expression was scored as negative (< 1%) or positive (≥ 1%) by immunohistochemistry. All 4 patients with Langerhans cell sarcoma (100%) and 6 of 22 pediatric (age < 18 years) patients with Langerhans cell histiocytosis (27.3%) had positive results for IGF2BP3; however, 16 of 22 pediatric patients with Langerhans cell histiocytosis (72.7%) and all 15 adult (age ≥ 18 years) patients with Langerhans cell histiocytosis (100%) had a negative result. Among patients with Langerhans cell histiocytosis, IGF2BP3 expression was independent of sex, location, prognosis, and BRAF V600E staining results. Taken together, these results indicate that IGF2BP3 expression may be a helpful marker for distinguishing Langerhans cell sarcoma from Langerhans cell histiocytosis in adult patients.
AB - Langerhans cell neoplasms, which include Langerhans cell histiocytosis and Langerhans cell sarcoma, are tumors that originate from dendritic cells. Langerhans cell sarcoma is defined as a high-grade neoplasm with overtly malignant cytological features and the Langerhans cell-like phenotype, and generally has a poorer prognosis and more aggressive phenotype than Langerhans cell histiocytosis. Insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types; its expression is often associated with a poor prognosis and aggressive phenotype. Here, we used immunohistochemistry to evaluate IGF2BP3 expression in Langerhans cell neoplasms. IGF2BP3 expression was scored as negative (< 1%) or positive (≥ 1%) by immunohistochemistry. All 4 patients with Langerhans cell sarcoma (100%) and 6 of 22 pediatric (age < 18 years) patients with Langerhans cell histiocytosis (27.3%) had positive results for IGF2BP3; however, 16 of 22 pediatric patients with Langerhans cell histiocytosis (72.7%) and all 15 adult (age ≥ 18 years) patients with Langerhans cell histiocytosis (100%) had a negative result. Among patients with Langerhans cell histiocytosis, IGF2BP3 expression was independent of sex, location, prognosis, and BRAF V600E staining results. Taken together, these results indicate that IGF2BP3 expression may be a helpful marker for distinguishing Langerhans cell sarcoma from Langerhans cell histiocytosis in adult patients.
KW - IGF2BP3
KW - Immunohistochemistry
KW - Langerhans cell histiocytosis
KW - Langerhans cell neoplasm
KW - Langerhans cell sarcoma Tohoku J. Exp. Med., 2021 September, 255 (1), 27-31
UR - http://www.scopus.com/inward/record.url?scp=85114924184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114924184&partnerID=8YFLogxK
U2 - 10.1620/tjem.255.27
DO - 10.1620/tjem.255.27
M3 - Article
C2 - 34497165
AN - SCOPUS:85114924184
VL - 255
SP - 27
EP - 31
JO - Tohoku Journal of Experimental Medicine
JF - Tohoku Journal of Experimental Medicine
SN - 0040-8727
IS - 1
ER -